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Identification of CISK, a new member of the SGK kinase family
that promotes IL-3-dependent survival
Dan Liu, Xiaohong Yang and Zhou Songyang
The signaling pathways for cell survival are much less
well understood than those for apoptosis [1]. Many
mammalian cell-survival factors have been identified,
either biochemically or from genetic studies in other
organisms. Effective genetic methods that allow
systematic study of anti-apoptosis genes in mammalian
cells remain to be established, however. To achieve this
goal, we used a new genetic screening method using
enhanced retroviral mutagen (ERM) vectors to identify
factors that mediate IL-3-dependent survival of
hematopoietic cells. Both known and novel mediators
of cell survival were identified, including Bcl-xL,
phosphatidylinositide 3-kinase (PI 3-kinase), Akt and
cytokine-independent survival kinase (CISK). CISK is a
PX-domain-containing serine/threonine kinase
homologous to serum- and glucocorticoid-regulated
protein kinase (SGK). We showed that CISK acts
downstream of the PI 3-kinase cascade in vivo and may
function in parallel to Akt by phosphorylating Bad and
the transcription factor FKHRL1. The distinct
subcellular localization of CISK, however, suggests
that it acts in different signaling cascades from Akt.
Our results demonstrate the power of ERM to identify
key genes involved in cell-survival signaling.
Furthermore, CISK is the first SGK family member that
has been shown to promote survival, pointing to the
possibility that other SGK family proteins may also
function in survival pathways.
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Results and discussion
The new large-scale mammalian genetic screening
method we have developed takes advantage of the
random nature of retroviral integration and uses engi-
neered sequences to mutagenize endogenous genes.
Several features were engineered into the ERM vectors
(Figure 1) as an improvement on conventional retroviral
vectors [2]. A mutagenesis tag (ERM Tag) and a splice
donor sequence were added in the U3 region of the 3′ long
terminal repeat (LTR) to tag endogenous genes. The
ERM Tag sequences include an epitope tag and a
myristylation signal to increase mutagenesis efficiency,
and to allow direct cloning of the targeted genes by RT-
PCR. Furthermore, expression of the ERM Tag was con-
trolled by a promoter that could be turned off by
tetracycline [3], making the ERM system conditional and
enabling analysis of authentic integration events rather
than spontaneous mutations. Insertional gene activation
by ERM integration may occur either through the genera-
tion of a fusion molecule between ERM Tag and endoge-
nous sequences (via the engineered splice donor), or by
transcriptional activation of the endogenous genes (via the
ERM retroviral enhancer) (Figure 1).
The ERM strategy was used to screen for anti-apoptosis
genes in IL-3-dependent 32D cells. A set of three ERM
constructs in three reading frames was constructed to gen-
erate viruses for infection of 32D cells (multiplicity of
infection < 1) which undergo apoptosis upon withdrawal of
IL-3 (see Supplementary material for full methodological
details). Approximately 100 mutant clones were isolated.
Figure 1
Design of the ERM vector. The ERM constructs are pBabe-puro based
vectors as shown at the top. Sequences that encode the splice donor
(SD), ERM Tag (epitope tag and myristylation signal), and the
tetracycline-responsive promoter are represented by boxes in the 5′
region of the 3′ LTR. The arrow indicates the direction of transcription.
During ERM replication by reverse transcription, the engineered
sequences are duplicated to the 5′ LTR as well. ERM virus integration
may either occur close to an endogenous exon, allowing splicing and
generation of fusion products, or result in increased transcription of the
locus as a result of the activity of the ERM enhancer. SA, splice acceptor.
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Of the ~40 clones analyzed, both known and novel media-
tors of cell survival were identified, including a diverse
array of factors such as cytokines, cytokine receptors and
protein kinases (Table 1). Many of these genes (such as
those for Bcl-xL [4], c-Abl [5], PI 3-kinase and Akt/PKB
[6,7]) have been implicated in the IL-3 pathway. One of
the novel survival mediators is a serine/threonine kinase
we named CISK (Figure 2a). CISK is homologous to SGK
[8], but, unlike SGK, it contains a putative amino-terminal
Phox-homology (PX) domain found in NADPH oxidase
and sorting nexins [9,10]. The kinase domain of CISK is
also very similar to Akt (51%). Notably, the two regulatory
residues shown to be important for modulating SGK
(Thr256 and Ser421) and Akt (Thr308 and Ser473) activi-
ties are also conserved in CISK (Thr320 and Ser486).
CISK appears to be widely expressed, predominantly in
the mouse heart, spleen and 7-day embryo.
CISK is likely to be the mouse homolog of human SGK3.
The carboxy-terminal sequence (from Met68) of CISK is
96% identical to hSGK3, whose cellular function remains
unknown [11]. However, the CISK amino-terminal 67
amino acids encode half of the predicted PX domain and
are absent from the reported hSGK3 sequence. This dif-
ference in length may be accounted for by a difference in
translational start sites. To determine whether Met1 or
Met68 is utilized as the initial methionine, full-length
CISK mRNA was translated in vitro as well as expressed in
293T cells. In both systems the predominant CISK
product was ~65 kDa, consistent with Met1 being the
initial methionine (Figure 2a). These data suggest that the
reported hSGK3 may be a partial sequence. 
Because the ERM promoter was tetracycline regulatable
(Figure 1), the original CISK clone isolated during the
screen was tested for tetracycline responsiveness. This
was positive (Figure 2b), indicating that CISK was the
retrovirally targeted gene responsible for the survival
phenotype. The anti-apoptotic function of CISK did not
involve an autocrine mechanism (data not shown). In
addition, expression of either wild-type or activated
(myristylated) CISK was able to protect 32D cells after
IL-3 withdrawal (Figure 2c). Activated CISK could also
protect IL-3-dependent BAF3 cells. Furthermore, a
kinase-dead CISK mutant (K191A) did not inhibit cell
death, suggesting that the kinase activity is critical. In
contrast, deletion of the PX domain (Myr-CISK∆PX)
consistently enhanced survival, suggesting that this
domain may negatively regulate CISK activity. The
identification of CISK from our survival screen provided
the first clue to CISK function. It also raised the intrigu-
ing possibility that other SGK family kinases may also
regulate cell survival.
The sequence homology between CISK and Akt suggests
a role of CISK in PI 3-kinase survival pathways, possibly
interacting with Akt substrates. Indeed, we found that
CISK specifically phosphorylates histone H2B in a kinase-
dependent manner. We next investigated whether the
kinase activity of CISK might be regulated by IL-3 and PI
3-kinase. As shown in Figure 2d, an almost 7 ± 1.2-fold
increase in H2B phosphorylation could be detected within
1 minute after IL-3 addition in 32D cells expressing wild-
type CISK. Importantly, such activation was almost com-
pletely abolished by wortmannin. These data show that
the activity of CISK can be regulated by IL-3, and support
the notion that CISK has a role in IL-3-mediated survival
downstream of PI 3-kinase and possibly overlapping in
function with Akt.
One target of Akt in vivo is the forkhead family of transcrip-
tion factors (FKHRs) such as FKHRL1 [12]. FKHRs may
upregulate Fas ligand and thereby induce apoptosis. Sup-
porting the model that CISK may have overlapping func-
tions with Akt and target FKHRs, co-expression of activated
or wild-type CISK and FKHRL1 resulted in dose-depen-
dent inhibition of FKHRL1 activity (Figure 3a). Further-
more, kinase-dead CISK failed to inhibit FKHRL1 activity.
Therefore, CISK can target FKHRs in vivo, probably con-
tributing to its anti-apoptosis activity.
IL-3 has been shown to increase expression of Bcl-xL and
Bcl-2 [13,14]. CISK may therefore promote survival by
regulating Bcl-2 family proteins. Increased levels of Bcl-xL
were sustained in cells expressing activated CISK
(Figure 3b), supporting this hypothesis. The level of Bcl-2
was also slightly increased (data not shown). IL-3 and Akt
can induce Bad phosphorylation, which in turn promotes
homodimerization of Bcl-xL or Bcl-2, thereby attenuating
1234 Current Biology Vol 10 No 19
Table 1
Sample list of known and novel survival mediators identified
from the ERM screen.
Gene loci IL-3 pathway  
targeted Function TF* RF† involvement
IL-3 Cytokine 1 RF3 Yes
GM-CSFRα‡ Cytokine receptor 1 RF3 Yes
c-Abl Tyrosine kinase 5 RF2 Yes
PI 3-kinase Lipid kinase 1 RF1 Yes
Akt Ser/Thr kinase 1 RF1 Yes
Bcl-xL Mitochondrial integrity 1 RF1 Yes 
Hck Tyrosine kinase 2 RF1 Yes
Ctk Tyrosine kinase 1 RF1 ?
GDI3 GDP dissociation inhibitor 2 RF2 ?
Gda Guanine deaminase 2 RF1 ?
CISK Ser/Thr kinase 1 RF1 Yes
All clones shown are tetracycline responsive. *TF, targeting frequency,
indicating the number of independent clones in which the gene was
identified. †RF, the reading frame of the ERM Tag sequences in the
original ERM construct (three ERM constructs in three reading frames
were used for the screen). ‡GM-CSFR, receptor for granulocyte-
macrophage colony-stimulating factor. 
cell death [7,15]. We found that expression of activated
CISK resulted in an increase in the amount of phosphory-
lated Bad (Figure 3b). These data strongly indicate that
CISK may mediate cell survival function through modu-
lating Bcl-2 family proteins. Such interactions, however,
did not appear to require Akt activation. The level of
phosphorylated Akt did not change in cells expressing
myristylated CISK (Figure 3b), suggesting that CISK may
function in parallel to Akt.
The unique domain organization of CISK suggests that it
may function in pathways distinct from Akt. The distinct
subcellular localization of CISK supports this hypothesis.
In agreement with previous findings [16], we found that
Akt was localized to the cytoplasm and nucleus in the
presence of serum, with larger amounts in the nucleus
(Figure 3c). In contrast, CISK appeared to be localized in
vesicular compartments, consistent with the localization of
many PX-domain-containing sorting proteins such as SNX
[17]. In addition, the PX domain is required for CISK sub-
cellular localization, because truncation of the PX domain
resulted in diffused staining (Figure 3c). These data indi-
cate that CISK and Akt may function differently. Interest-
ingly, the addition of a myristylation signal to full-length
CISK did not significantly change its localization
(Figure 3d), suggesting a dominant role for the PX domain
in targeting CISK.
We have used the ERM genetic screening method to
search for survival genes throughout the genome. Exami-
nation of the remaining ~60 clones may yield more sur-
vival genes, including those in the Ras and MAP kinase
cascades, the IAP family, or the JAK/STAT pathway. Our
results demonstrate the reliability and power of this
approach to gene identification compared with conven-
tional retroviral mutagenesis [18]. The ERM screen has
also been successful in identifying transforming genes in
NIH 3T3 cells (our unpublished work). The method can
therefore be adapted for screening genes involved in
diverse signaling pathways.
We present here the first evidence that CISK, a member
of the SGK family, can effectively block apoptosis
induced by IL-3 withdrawal. Other SGK family kinases
lack the PX domain and their involvement in cell-sur-
vival signaling remains to be determined. CISK may
prevent cell death by upregulating Bcl-xL expression and
inhibiting the pro-apoptotic proteins Bad and FKHRs.
CISK probably directly phosphorylates Bad and FHKRs,
as these proteins contain the CISK consensus phosphory-
lation site (RXRXXS/T, where X is any amino acid) [11].
Because CISK expression does not involve Akt activa-
tion, and Bad and FKHRs are also Akt substrates, our
findings strongly indicate that CISK functions in parallel
to Akt. Although CISK and Akt share some similarities,
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Figure 2
CISK is a PX-domain-containing
serine/threonine survival kinase. (a) The domain
structure of CISK is shown at the top, with the
two conserved regulatory residues indicated.
For the gels below, full-length (CISK) and
truncated CISK (Met68-CISK) were
transcribed and translated in vitro (left); 293T
cells (control) and those expressing full-length
FLAG-tagged CISK (CISK–FLAG) were
analyzed by western blotting (right). (b) The
ERM-targeted CISK clone loses the ability to
survive in IL-3-free media containing
tetracycline (Tet). 32D-tTA, control cells
expressing the Tet-controlled transactivator in
IL-3 media [3]. (c) CISK inhibits apoptosis
induced by IL-3 withdrawal. The graph on the
left shows 32D cells expressing wild-type CISK
(open circles), activated myristylated CISK
(Myr-CISK; filled diamonds), myristylated CISK
lacking the PX domain (Myr-CISK∆PX; filled
squares), kinase-dead CISK (CISK-K191A;
open squares), or a mock vector (filled circles),
and deprived of IL-3. The percentages of live
cells at 17, 24 and 48 h were determined. The
right-hand graph shows the survival of BAF3
cells expressing Myr-CISK (open squares) or a
mock vector (open circles). Error bars indicate
standard errors. (d) IL-3 activates CISK kinase
activity. Mock-infected 32D cells (Mock) or
those expressing hemagglutinin (HA)-tagged
wild-type CISK (HA–CISK) were treated with
IL-3 for 0, 1, 5, 10 or 20 min. Kinase assays
were performed on anti-HA immunoprecipitates
using histone H2B as a substrate. Activation of
CISK kinase activity can be inhibited by
pretreatment of 100 nM wortmannin (Wort).
Anti-HA antibodies were used to detect
HA–CISK.
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they are distinct kinases. Akt has an amino-terminal
pleckstrin-homology (PH) domain, and the activation of
Akt mainly depends on direct binding of the PH domain
to D3-phosphoinositide lipids and phosphorylation by
3-phosphoinositide-dependent kinase 1 (PDK1) [19]. On
the basis of sequence homology between CISK, Akt and
other SGKs, CISK probably acts directly downstream of
PDK1. However, CISK contains a PX domain, which
may function similarly to the PH domain, or act as a
protein–protein interaction domain and recruit signaling
molecules other than phospholipids [10]. If the latter is
the case, CISK may respond to and integrate other cell-
survival signals in addition to PI 3-kinase and thereby
function in pathways distinct from Akt. Consistent with
this, we found that the localization of CISK depended on
its PX domain and differed from that of Akt. The differ-
ential subcellular localization of CISK and Akt may thus
allow these two kinases to be regulated by and target dif-
ferent pathways.
Supplementary material
Supplementary material including Materials and methods and two addi-
tional figures showing tissue distribution and sequence alignment of
CISK and expression of various CISK constructs is available at
http://current-biology.com/supmat/supmatin.htm.
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Figure 3
CISK functions in parallel to but distinct from Akt. (a) CISK can inhibit
FKHRL1. 293T cells were transiently transfected with a mock vector,
FKHRL1 alone (50 ng), FKHRL1 plus myristylated CISK (Myr-CISK,
0.1 µg, 0.3 µg or 0.5 µg) or wild-type CISK (WT CISK, 0.5 µg), or
FKHRL1 plus myristylated CISK with K191A mutation (Myr-CISK
K191A, 0.3 µg). The FKHRL1 activity was measured in a luciferase
assay using β-gal as transfection control. Error bars indicate standard
errors. (b) CISK may regulate Bcl-2 family members and act in parallel
to Akt. Western analysis of 32D cells deprived of IL-3 for 0, 3 or 5 h
was done using antibodies against phospho-Bad112 (p-Bad), Bad,
Bcl-xL, phospho-Akt473 (p-Akt), and Akt. Anti-GRB2 antibodies were
used as loading controls. Localization of (c) HA–Akt and various
HA-tagged CISK or (d) FLAG-tagged CISK constructs were examined
in 3T3 cells via immunofluorescence using anti-HA or FLAG
antibodies. Left panels, staining with FITC-conjugated secondary
antibodies. Right panels, DAPI staining of the corresponding cells.
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